Pacira BioSciencesFRA:82P +2.75%75 Days Inventory is 377.51 as of Mar. 2026, which is 99% above its 10-year median of 190.17. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review. Among 919 Drug Manufacturers companies, Pacira BioSciences ranks worse than 90.32% on this metric.
The historical rank and industry rank for Pacira BioSciences's Days Inventory or its related term are showing as below:
FRA:82P'
s Days Inventory Range Over the Past 10 Years
Min: 150.89 Med: 190.17 Max: 357.09
Current: 357.09
During the past 13 years, Pacira BioSciences's highest Days Inventory was 357.09. The lowest was 150.89. And the median was 190.17.
FRA:82P's Days Inventory is ranked worse than 90.32% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs FRA:82P: 357.09
Pacira BioSciences's Days Inventory
increased
from Mar. 2025 (349.91) to Mar. 2026 (377.51).
It might indicate that Pacira BioSciences's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pacira BioSciences's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.24.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacira BioSciences's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.85.
Pacira BioSciences (FRA:82P) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pacira BioSciences's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacira BioSciences's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Pacira BioSciences Days Inventory Related Terms
Pacira BioSciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a Days Inventory of 377.51 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pacira BioSciences and its competitors. This is 99% above median its historical median of 190.17. Over the past decade, Pacira BioSciences' Days Inventory has ranged from 150.89 to 357.09. According to the industry distribution chart, Pacira BioSciences ranks #830 out of 919 companies in the Drug Manufacturers industry, placing it in the top 90.3%.
Is Pacira BioSciences' Days Inventory too high?
Pacira BioSciences' current Days Inventory of 377.51 is 99% above median its 10-year median of 190.17. Over the past 10 years, this metric has ranged from a low of 150.89 to a high of 357.09. The Drug Manufacturers industry median Days Inventory is 164.48. Pacira BioSciences' value of 377.51 is 129.5% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #830 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Days Inventory compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #830 out of 919 companies for Days Inventory. This places Pacira BioSciences in the lower half of its industry. The industry median Days Inventory is 164.48. Pacira BioSciences' value of 377.51 is 129.5% above this benchmark. Historically, Pacira BioSciences' own Days Inventory has ranged from 150.89 to 357.09 over the past decade. While the company's 10-year median is 190.17 vs. the industry median of 164.48, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Days Inventory of 377.51 is 129.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Days Inventory is 377.51, which is 99% above median its own 10-year median of 190.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Days Inventory of 377.51. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Days Inventory is 377.51, which is 99% above median its 10-year median of 190.17 and 129.5% above the Drug Manufacturers industry median of 164.48. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Days Inventory is 377.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.
Key valuation signals for FRA:82P:
Days Inventory: 377.51 (99% above median its 10-year median of 190.17)
GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
Industry Position: 129.5% above the Drug Manufacturers median (#830 of 919)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for FRA:82P
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
